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The safety and efficacy of liver gene therapy based on adeno-associated viral (AAV) vector serotype 8 is being tested in haemophilia B patients and the results are extremely encouraging. We have recently shown that a similar approach results in long-term systemic release of therapeutic levels of arylsulfatase B enzyme in a feline model of mucopolysaccharidosis VI (MPS VI), a severe, systemic, lysosomal storage disease without central nervous system involvement and, thus, with the highest potential to benefit from liver gene therapy. While our data bode well for further clinical translation of liver gene therapy for MPS VI, the potential toxicity of the treatment has not yet been evaluated. Although a formal toxicity study under good laboratory practice conditions has not been performed, we evaluated mortality, weight loss, hepatic and haematological markers in 60 cats, all but one affected by MPS VI. Fifty-one received intravenous infusions of 2×10^11^-6×10^13^ genome copies/kg of AAV2/8-TBG-felineARSB (n=45) or EGFP (n=6) either at post-natal day 2 (n=17) or 50 (n=34). No events of death were documented in the nine untreated MPS VI cats, whereas in seven of those treated with AAV2/8 deaths were reported including those due to: feline infectious peritonitis (FIP) due to coronavirus (n=4); peritoneal abscess one day after AAV treatment (n=1, ileum and colon dark red and a 2mm abscess on the base of tail); liver bleeding one day after a liver biopsy (n=1, in this case a liver mass with a histological diagnosis of adenoma was present; no eGFP+ cells nor AAV genome copies were found in the liver biopsy); unknown cause (n=1, erroneously no autopsy was performed in this animal). No significant differences in weight, liver function biomarkers (serum transaminases, gamma glutamyl transpeptidase and bilirubin) or haematology (white blood count, segmented neutrophils, and lymphocytes) were found between AAV-treated and untreated cats. We did not consider high values of hepatic and haematological markers measured in conjunction with liver biopsies or FIP development. We conclude that liver-directed AAV2/8-mediated gene transfer was not associated with increased values of liver function or haematological biomarkers or with increased mortality in MPS VI cats.
